冠福股份(002102) - 冠福股份调研活动信息

Group 1: Investment Overview - The company has established a joint venture, Yiman Te, with DSM for vitamin E and its intermediates [1] - Tianke Pharmaceutical is a collaboration between Nengte Technology and Tianjin Institute of Pharmaceutical Research [1] - The joint venture Yiman Te has exceeded profit expectations, indicating a strengthening partnership with DSM [2] Group 2: Future Investment Plans - The company is preparing investment plans for the next three years (2024-2026) focusing on new project development [1] - The company aims to implement large-scale project investments annually, emphasizing technological innovation and high-quality projects [2] Group 3: Market Insights - The global vitamin E market is expected to grow by 3% annually, with stable prices and high profit margins for Yiman Te [2] - Major players in the global vitamin E market include BASF and DSM, with no significant changes in market dynamics [2] Group 4: Financial Performance - The company's net profit decreased significantly in the first half of 2023 due to previous losses from 2018, but the current performance remains stable when excluding these factors [2] - The company has reduced its debt significantly, leading to a decrease in loss recovery in 2023 compared to the previous year [2]